The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
New York Heart Association (NYHA) Class
Timeframe: From time of ATTR-CM diagnosis up to 5 years
Outpatient Diuretic Intensification
Timeframe: From time of enrollment for up to 5 years
Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Score
Timeframe: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Timeframe: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Patient Global Impressions - Change (PGI-C)
Timeframe: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Patient Global Impressions - Severity (PGI-S);
Timeframe: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Treatment Satisfaction Questionnaire for Medication version 9 (TSQM-9)
Timeframe: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years